EVARMED develops a new injectable solution for the treatment of osteoarthritis symptoms. The solution replaces pathological synovial fluid with the alternative having the same rheological properties as hyaluronic acid-based products but with greater resistance to joint inflammation. This results in less frequent administration for joint disease patients. The manufacturing process is based on proprietary technology, which additionally is simple and cost-effective, enabling broader access to new viscosupplementation therapy. The product can also be developed as a platform for new advanced regenerative strategies.